ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,420.26
-0.22%
Dow Jones
40,003.59
0.34%
Gold vs US Dollar
2,413.935
0.00%
Brent Oil
83.76
0.00%
Bitcoin
67,011.87
0.11%
Pepperstone
Advertisement
Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Citius Pharmaceuticals Inc (CTXR)

  7. Citius Pharmaceuticals Inc (CTXR) News

Citius Pharmaceuticals (CTXR)

Citius Pharmaceuticals Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:CTXR
DateTimeSourceHeadlineSymbolCompany
14/05/202421:26Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CTXRCitius Pharmaceuticals Inc
14/05/202421:05Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CTXRCitius Pharmaceuticals Inc
14/05/202421:05PR Newswire (US)Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:CTXRCitius Pharmaceuticals Inc
10/05/202413:30PR Newswire (US)Citius Pharmaceuticals to Participate in Upcoming EF Hutton and H.C. Wainwright Investor ConferencesNASDAQ:CTXRCitius Pharmaceuticals Inc
30/04/202421:05PR Newswire (US)Citius Pharmaceuticals Announces Closing of $15 Million Registered Direct OfferingNASDAQ:CTXRCitius Pharmaceuticals Inc
26/04/202413:00PR Newswire (US)Citius Pharmaceuticals Announces $15 Million Registered Direct OfferingNASDAQ:CTXRCitius Pharmaceuticals Inc
11/04/202413:30PR Newswire (US)Citius Pharmaceuticals Announces Addition of City of Hope to UMN's Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell LymphomaNASDAQ:CTXRCitius Pharmaceuticals Inc
04/04/202413:30PR Newswire (US)Citius Pharmaceuticals to Present at the LD Micro Invitational XIV Investor ConferenceNASDAQ:CTXRCitius Pharmaceuticals Inc
18/03/202412:30PR Newswire (US)Citius Pharmaceuticals Announces FDA Acceptance of the BLA Resubmission of LYMPHIR™ (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell LymphomaNASDAQ:CTXRCitius Pharmaceuticals Inc
07/03/202413:30PR Newswire (US)Citius Pharmaceuticals, Inc. Secures $2.4 million through New Jersey Economic Development ProgramNASDAQ:CTXRCitius Pharmaceuticals Inc
04/03/202405:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:CTXRCitius Pharmaceuticals Inc
26/02/202412:30PR Newswire (US)Citius Pharmaceuticals Announces Filing of Form S-3 Shelf Registration Statement to Replace Expiring Prior Shelf RegistrationNASDAQ:CTXRCitius Pharmaceuticals Inc
23/02/202421:23Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:CTXRCitius Pharmaceuticals Inc
23/02/202421:18Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:CTXRCitius Pharmaceuticals Inc
23/02/202413:30PR Newswire (US)Citius Pharmaceuticals to Participate in Upcoming BIO CEO and Sidoti Investor ConferencesNASDAQ:CTXRCitius Pharmaceuticals Inc
15/02/202413:45Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CTXRCitius Pharmaceuticals Inc
14/02/202421:40Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CTXRCitius Pharmaceuticals Inc
14/02/202421:30PR Newswire (US)Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:CTXRCitius Pharmaceuticals Inc
14/02/202414:18Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CTXRCitius Pharmaceuticals Inc
14/02/202413:01PR Newswire (US)Citius Pharmaceuticals Resubmits the Biologics License Application of LYMPHIR™ (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell LymphomaNASDAQ:CTXRCitius Pharmaceuticals Inc
26/01/202421:15Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:CTXRCitius Pharmaceuticals Inc
26/01/202421:08Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:CTXRCitius Pharmaceuticals Inc
26/01/202421:05Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:CTXRCitius Pharmaceuticals Inc
23/01/202421:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CTXRCitius Pharmaceuticals Inc
23/01/202413:30PR Newswire (US)Citius Pharmaceuticals Announces Nomination of Pharmaceutical Executive Robert J. Smith to its Board of DirectorsNASDAQ:CTXRCitius Pharmaceuticals Inc
05/01/202421:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CTXRCitius Pharmaceuticals Inc
02/01/202421:04Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CTXRCitius Pharmaceuticals Inc
02/01/202413:31PR Newswire (US)Citius Pharmaceuticals Completes Enrollment in Pivotal Phase 3 Trial of its Mino-Lok® Therapeutic to Salvage CathetersNASDAQ:CTXRCitius Pharmaceuticals Inc
02/01/202413:30PR Newswire (US)Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2023 Financial Results and Provides Business UpdateNASDAQ:CTXRCitius Pharmaceuticals Inc
29/12/202321:05Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:CTXRCitius Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:CTXR

Your Recent History

LSE
JZCP
Jz Capital Partners
LSE
0QF9
Value8 Nv
LSE
0JZZ
Medical Properties
LSE
CMAU
Cma Global Hedge Pcc
LSE
AEL
Anzon Energy
EU
FDE
Francaise Energie
LSE
CNCT
Connect
LSE
0JW9
Mei Pharma
LSE
WCRX
LSE
APRA
EU
ALHEO
H2O Innovation
LSE
GGK
Gamingking
LSE
COLT
Colt Telecom
LSE
0R0G
Mondelez
LSE
GGP
Greatland Gold
NYSE
WHR
Whirlpool
Delayed Upgrade Clock
    ADVFN Logo

    United Kingdom
    Company
    Business
    Popular
    Get The App

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved